Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Cancer is one of the leading causes of death worldwide. In Canada, cancer accounts for 30% of all deaths, and half of all Canadians will develop cancer in their lifetime. Many cancers can be prevented or controlled through early detection, but the availability of such tests is scarce and a reliable general biomarker for different types of cancers has not been yet discovered. Moreover, cancer survivors are at greater risk of developing a second cancer, and affordable and safe monitoring for the rest of their lives is not available. We propose the development of a serological test for early diagnosis of cancer based on the activity of an enzyme that is upregulated in cancer tissues. This enzyme is able to modify a drug approved by the FDA termed amantadine, which can be measured in urine. We also propose to validate the performance of the kit in clinical samples of patients with lung cancer. Moreover, through our network of collaborators, we expect to distribute the methodology in different points of care in Canada and abroad (USA and Bangladesh).
This project is innovative because it uses inexpensive antibodies produced in bacteria against the modified amantadine detected in urine.
Horacio Bach
Rim Alyeldin Hassan Noureldin Aly
BioMark Technologies Inc
Medicine
Professional, scientific and technical services
University of British Columbia
Accelerate
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.